Disposal of own shares
Brussels (Belgium), 7 March 2022 – 20:00 (CET) – Regulated information
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:
In addition to these exercises, on 2 March 2022, in accordance with the vesting rules under its 2020 and 2021 LTI plans, UCB SA/NV has delivered for free a total of 328 UCB shares OTC to 2 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 2 March 2022 was € 99,82.
This press release is available on UCB SA/NV’s website via the following link.
For further information, contact UCB:
T +32 2 559 94 14
T+32 2 559 92 64
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Stay up-to-date on the latest news and information from UCB